$49 per month*
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Biogen’s revenue breakdown by product from Q1 2016 onwards, split across Multiple Sclerosis (MS), Spinal Muscular Atrophy, Alzheimer’s disease, Biosimilars and Others, reported on a quarterly basis.
Biogen has been making medicines for the treatment of diseases like Multiple Sclerosis (MS), SMA, chronic lymphocytic leukemia (CLL), severe plaque psoriasis, non-Hodgkin’s lymphoma, follicular lymphoma, primary progressive MS (PPMS), relapsing MS (RMS), and other conditions. It has the research and development of more than two decades, for treating MS, resulting in a leading portfolio of MS treatments.
Biogen’s Revenue Breakdown by Product
|Product||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
|MS Product revenue||$1,984.90||$1,529.20||$1,556.00||70.54%|
|Spinal Muscular Atrophy||$494.40||$499.70||$444.10||20.13%|
(All the values are in millions, except percentages)
MS Product revenue
Biogen uses AVONEX, TECFIDERA, VUMERITY, PLEGRIDY, FAMPYRA, and TYSABRI for the treatment of Multiple Sclerosis (MS).
This product segment contributes 70.54% to the total revenue generated by all the products by Biogen in Q3 2021. It has generated a revenue of $1,556 million in Q3 2021, which is an increase of 1.75% on a quarter-on-quarter basis, from $1,529.20 million earned in Q2 2021. MS product segment shows a decline of 21.6% on a year-on-year basis, from $1,984.9 million in Q3 2020 to $1,556 million in Q3 2021.
Spinal Muscular Atrophy (SMA)
Biogen uses the product SPINRAZA for the treatment of Spinal Muscular Atrophy (SMA).
Revenue by products for SMA contributed 20.13% to the total revenue earned by the entire product mix in Q3 2021. SMA generated a revenue of $444.10 million in Q3 2021, showing a decline of 11.13% from $499.70 million on a quarter-on-quarter basis. This decline was equal to $55.60 million. This product segment shows a decline of 10.17% on a year-on-year basis, from $494.4 million in Q3 2020 to $444.1 million in Q3 2021.
ADUHELM, a new product introduced for the treatment of Alzheimer’s disease was launched in Q2 2021, and therefore doesn’t have enough data to calculate the year-on-year growth.
The product for Alzheimer’s disease contributes 0.01% to the total revenue generated by the product mix in Q3 2021. Revenue generated from this product in Q3 2021 was $0.30 million, which is a decline of 81.25% on a quarter-on-quarter basis from the previous quarter, where the revenue stood at $1.60 million.
Biogen has financial rights and certain businesses regarding RITUXAN, OCREVUS, RITUXAN HYCELA, and GAZYVA.
This product segment contributes 9.19% to the total revenue of the product mix in Q3 2021. It earned $202.80 million in Q3 2021, which is a rise of 0.20% on a quarter-on-quarter basis as compared to the revenue generated of $202.40 million in Q2 2021. The biosimilar segment shows a decline of 2.45% on a year-on-year basis, from $207.9 million in Q3 2020 to $202.8 million in Q3 2021.
FUMADERM is the product termed as other products used for the treatment of severe plaque psoriasis, and other potential anti-CD20 therapies under the company’s collaboration arrangements.
Other sources of revenue contributes 0.11% to the total revenue generated by product mix by Biogen Inc. in Q3 2021. A revenue of $2.50 million was generated by this product segment in Q3 2021, which is a decline of 19.35% on a quarter-on-quarter basis, from $3.10 million in Q2 2021. This decline was equivalent to $0.60 million. The decline on a year-on-year basis for revenue from other products is the same as the decline on the quarter-on-quarter basis, amounting to 19.35%.
In 1978, Biogen was founded in Geneva as Biotechnology Geneva by several prominent biologists, Kenneth Murray, Phillip Allen Sharp, Walter Gilbert, and Heinz Schaller. This company’s core focus areas are MS/Neuro-immunology, Alzheimer’s Disease/Dementia, Neuro-muscular Disorders, Movement Disorders, Ophthalmology, Neuro-psychiatry, Immunology, Actual Neurology, and Neuropathic Pain. It is developing, discovering, and delivering for its core growth areas. Through commercialization activities and drug development, Biogen Inc. is reducing the cost burden for healthcare systems. The common stock of Biogen is publicly traded on the NASDAQ under the symbol “BIIB”.
Did you like Biogen’s revenue breakdown by product statistic?
Access more such key performance indicator (KPI) data points, on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.